
Ind-Swift Laboratories Ltd is Rated Hold
2026-11-16 10:11:45Ind-Swift Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Ind-Swift Laboratories Ltd is Rated Hold
2026-11-05 10:12:12Ind-Swift Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read MoreInd-Swift Laboratories Gains 12.08%: 3 Key Factors Driving the Rally
2026-10-31 17:07:14Key Events This Week 26 Oct: Stock opens strong at Rs.337.95 (+3.10%) 27 Oct: Sharp rally to Rs.368.25 (+8.97%) on heavy volume 28 Oct: Moderate gain to Rs.379.45 (+3.04%) despite Sensex dip 29 Oct: Surge to Rs.408.85 (+7.75%) with record volume 30 Oct: New 52-week and all-time high intraday at Rs.426; closes lower at Rs.367.40 (-10.14%) Week OpenRs.327.80</...
Read More
Ind-Swift Laboratories Ltd Hits All-Time High of Rs 426 as Momentum Builds Across Timeframes
2026-10-30 09:32:03Extending a remarkable five-day winning streak, Ind-Swift Laboratories Ltd surged to a fresh all-time high of Rs 426 on 30 Oct 2026, marking a significant milestone in its recent rally. This advance comes amid sustained outperformance against the broader sector and a backdrop of strong technical momentum.
Read More
Ind-Swift Laboratories Ltd Reports Outstanding Quarterly Financial Performance Amid Strong Market Returns
2026-10-30 08:00:09Ind-Swift Laboratories Ltd has delivered an outstanding quarterly performance for September 2026, marking a significant improvement in its financial trend and market standing. The pharmaceutical and biotechnology company reported record-high revenues, profits, and margins, reflecting robust operational execution and a favourable market environment. This performance has contributed to a notable upgrade in its Mojo Grade from Sell to Hold, signalling renewed investor confidence.
Read More
Ind-Swift Laboratories Ltd is Rated Sell
2026-10-25 10:10:40Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 October 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreInd-Swift Laboratories Ltd Falls 0.55%: Downgrade and Mixed Technical Signals Shape Week
2026-10-17 17:06:16Key Events This Week 12 Oct: Stock opens at Rs.361.00, marginally down 0.03% 13 Oct: MarketsMOJO downgrades Ind-Swift Laboratories Ltd to Sell 14 Oct: Technical momentum shifts to mildly bullish amid mixed indicator signals 16 Oct: Week closes at Rs.359.10, down 0.55% for the week Week OpenRs.361.00 Week Close<div cla...
Read More
Ind-Swift Laboratories Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals
2026-10-14 08:23:47Ind-Swift Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 13 Oct 2026. This revision reflects a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments that collectively temper the stock’s appeal despite its impressive recent returns.
Read More
Ind-Swift Laboratories Ltd: Technical Momentum Shifts Amid Mixed Indicator Signals
2026-10-14 08:02:21Ind-Swift Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a modest day change of 0.08%, the stock’s technical parameters reveal a transition from a bullish to a mildly bullish trend, prompting a reassessment of its near-term outlook.
Read MoreAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript
10-Nov-2026 | Source : BSEPlease find enclosed transcript for earnings call held on November 04 2026.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
04-Nov-2026 | Source : BSEAudio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026.
Announcement under Regulation 30 (LODR)-Investor Presentation
04-Nov-2026 | Source : BSEPlease find enclosed investor presentation on un-audited financial results for the quarter ended September 30 2026
Corporate Actions
No Upcoming Board Meetings
Ind-Swift Laboratories Ltd has declared 10% dividend, ex-date: 20 Sep 11
No Splits history available
No Bonus history available
No Rights history available